The phase 3 study of the LAG-3 inhibitor missed its primary endpoint, leaving Regeneron reeling from...
Analysts ‘shaking heads’ after Regeneron melanoma drug fails to beat Keytruda in phase 3 trial
The phase 3 study of the LAG-3 inhibitor missed its primary endpoint, leaving Regeneron reeling from the second failure of a key late-stage program.
Author: Fierce Biotech
Read Original Article